News Center
Share the latest news with you
2021
2021-06-18
Completed First-Patient-Dose of Wee1 Inhibitor IMP7068 in the US and Received Chinese IND Approval
IMPACT Therapeutics Enters Shanghai New Bund International Business Zone
Hedgehog inhibitor (IMP5471) has been approved by NMPA to initiate clinical studies in China
ATR inhibitor IMP9064 has received the IND clearance from the FDA for the Phase I/II clinical study
About Us
News Recommendation
Copyright (c) 2013 IMPACT Therapeutics. All Rights Reserved 沪ICP备2024107649号 互联网药品信息证书编号:(沪)-非经营性-2025-0012 /Clinical Trial Privacy Notice / Privacy Notice / Legal Statement
